Press Release

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN

Lupin Wins Award for Operational Excellence in Manufacturing at India Pharma Awards 2019

New Delhi, December 3, 2019: Pharma major Lupin Limited won the prestigious award for 'Operational Excellence in Manufacturing' at the India Pharma Awards 2019. The jury panel which comprised senior leaders and veterans from the industry, chose Lupin as the recipient of this award for the company's innovative and consistent efforts in streamlining manufacturing operations and enabling quality excellence.

On receiving the award for operational excellence in manufacturing, **Rajendra B Chunodkar, President-Manufacturing Operations, Lupin Ltd.** said, "We are delighted to receive this award. The award acknowledges our focus, commitment and efforts to deliver high-quality and affordable medicines globally. It reinforces our commitment to this mission and encourages us to set higher benchmarks in manufacturing and continuous improvement."

Currently in its seventh year, the India Pharma Awards celebrates the advancements and achievements of the Indian Pharmaceutical Industry. The event was a part of the India Pharma Week 2019 held in Greater Noida (National Capital Region) between 26 – 28 November, 2019 and recognises companies and personnel from this industry.

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8th largest generics pharmaceutical company by revenues (June 30, 2019, Bloomberg LTM). The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT September 2019); 3rd largest Indian pharmaceutical company by global revenues (June 30, 2019, Bloomberg LTM); 6th largest company in the Indian Pharmaceutical Market and 5th largest generic pharmaceutical player in Japan (IQVIA MAT September 2019).

For the financial year ended March 31, 2019, Lupin's Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter at – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055

For further information or queries please contact:

Arvind Bothra
Head – Investor Relations and M&A / Corporate Communications
Email: arvindbothra@lupin.com
Ph: +91-22-66408237